Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Bastien Cabarrou"'
Autor:
Julie Savagner, Anne Ducassou, Bastien Cabarrou, Gregory Hangard, Marion Gambart, Anne-Isabelle Bertozzi, Eloise Baudou, Sergio Boetto, Delphine Larrieu, Anne Laprie
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 46, Iss , Pp 100777- (2024)
Objective: As craniospinal irradiation (CSI) is delivered more frequently by helical tomotherapy (HT) with few reports about late effects, we analysed all patients treated in our centre over an 11-year period. Methods and materials: Our study include
Externí odkaz:
https://doaj.org/article/086323619f4f4a86b74fdddff86f1a7f
Autor:
Gauthier Glemarec, Jean-Louis Lacaze, Bastien Cabarrou, Richard Aziza, Eva Jouve, Slimane Zerdoud, Eleonora De Maio, Carole Massabeau, Maxime Loo, Vincent Esteyrie, Mony Ung, Florence Dalenc, Francoise Izar, Ciprian Chira
Publikováno v:
Breast, Vol 69, Iss , Pp 424-427 (2023)
Externí odkaz:
https://doaj.org/article/b09eb453b47647b2a44b0002bcea4806
Autor:
Gauthier Glemarec, Jean-Louis Lacaze, Bastien Cabarrou, Richard Aziza, Eva Jouve, Slimane Zerdoud, Eleonora De Maio, Carole Massabeau, Maxime Loo, Vincent Esteyrie, Mony Ung, Florence Dalenc, Francoise Izar, Ciprian Chira
Publikováno v:
Breast, Vol 67, Iss , Pp 102-109 (2023)
Purpose: Local ablative treatment (LAT) is increasingly combined with systemic therapy in oligometastatic breast cancer (OMBC), without a high-level evidence to support this strategy. We evaluated the addition of LAT to systemic treatment in terms of
Externí odkaz:
https://doaj.org/article/a63ea51182e14f5598d6d0214ad99b4b
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Given the inherent challenges of conducting randomized phase III trials in older cancer patients, single-arm phase II trials which assess the feasibility of a treatment that has already been shown to be effective in a younger popu
Externí odkaz:
https://doaj.org/article/5f9863928f2c43abb9f68a4f84c5dad4
Autor:
Ayman Al Saati, Pierre Vande Perre, Julien Plenecassagnes, Julia Gilhodes, Nils Monselet, Bastien Cabarrou, Norbert Lignon, Thomas Filleron, Dominique Telly, Emilie Perello-Lestrade, Viviane Feillel, Anne Staub, Mathilde Martinez, Edith Chipoulet, Gaëlle Collet, Fabienne Thomas, Laurence Gladieff, Christine Toulas
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 18, p 14348 (2023)
Even though male breast cancer (MBC) risk encompasses both genetic and environmental aetiologies, the primary risk factor is a germline pathogenic variant (PV) or likely pathogenic variant (LPV) in BRCA2, BRCA1 and/or PALB2 genes. To identify new pot
Externí odkaz:
https://doaj.org/article/87e9553f379a47f987b5d51f4b3062b7
Autor:
Julia Gilhodes, Adèle Meola, Bastien Cabarrou, Guillaume Peyraga, Caroline Dehais, Dominique Figarella-Branger, François Ducray, Claude-Alain Maurage, Delphine Loussouarn, Emmanuelle Uro-Coste, Elizabeth Cohen-Jonathan Moyal, POLA Network
Publikováno v:
Cancers, Vol 15, Iss 12, p 3067 (2023)
Background. IDH mutant and 1p/19q codeleted oligodendrogliomas are the gliomas associated with the best prognosis. However, despite their sensitivity to treatment, patient survival remains heterogeneous. We aimed to identify gene expressions associat
Externí odkaz:
https://doaj.org/article/6a6ead4e719e4bd8991341057fe4ff0c
Autor:
Thomas Filleron, Sophie Le Guellec, Christine Chevreau, Bastien Cabarrou, Tom Lesluyes, Sabrina Lodin, Angélique Massoubre, Muriel Mounier, Muriel Poublanc, Frédéric Chibon, Thibaud Valentin
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The value of chemotherapy in soft tissue sarcoma (STS) remains controversial. Several expert teams consider that chemotherapy provides a survival advantage and should be proposed in high-risk (HR) patients. However, the lack of ac
Externí odkaz:
https://doaj.org/article/95159104642d44afbaa194669e03e23a
Autor:
Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher, Eric Delabesse
Publikováno v:
PLoS ONE, Vol 15, Iss 10, p e0238795 (2020)
Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a
Externí odkaz:
https://doaj.org/article/fec54a3e59a6476c836c6509f8d4321d
Autor:
Tina Lamy, Bastien Cabarrou, David Planchard, Xavier Quantin, Sophie Schneider, Michael Bringuier, Benjamin Besse, Nicolas Girard, Christos Chouaid, Thomas Filleron, Gaëtane Simon, Capucine Baldini
Publikováno v:
Cancers, Vol 14, Iss 1, p 92 (2021)
Background: Genomic and immunologic tumor biomarker testing has dramatically changed the prognosis of patients, particularly those treated for advanced/metastatic non-squamous non-small-cell lung cancer (aNSCLC) when access to targeted agents is avai
Externí odkaz:
https://doaj.org/article/87047e9785614b64afb65b5d8f2ae745
Autor:
Jean Louis LACAZE, Clémence Brac de la Perrière, Mony Ung, Florence Dalenc, Vincent Nicolai, Eleonore De Maio, Marion Montastruc, Bastien Cabarrou, Nils Monselet, Ciprian Chira, Gauthier Glemarec, Thibaut Cassou-Mounat
Publikováno v:
Cancer Research. 83:P1-05
Background: In order to determine the optimal treatment strategy for oligometastatic breast cancer (OMBC), effective and safe treatments for metastatic sites and sensitive and specific imaging techniques are needed. But it is also essential to know t